Ganti AK, Katranji K, Seal BS, et al. - Researchers analyzed treatment patterns in extensive stage small cell lung cancer (ES-SCLC) patients in the US following the introduction of immunotherapy (IO). For this purpose, they used real-world data from the Flatiron electronic medical records database regarding patients ≥18 years of age with an index ES-SCLC treatment from October 17, 2018 to November 30, 2019 (or no first-line (1L) treatment within 60 days of an index diagnosis during this time span). The inclusion/exclusion criteria were satisfied by 568 patients. The most often occurring 1L treatments included atezolizumab+carboplatin+etoposide, followed by carboplatin+etoposide, The most commonly seen and second-line (2L) treatments included atezolizumab+carboplatin+etoposide, topotecan, and other. Findings showed initiation of therapy usually occurred within a month of diagnosis in most of the patients with ES-SCLC. The receipt of 1L IO+chemotherapy (CT) was noted in over 50%, indicating how quickly IO has been adopted in the US. 1L treatment was not received by almost 14% patients and 2L therapy was received by only around 25% of 1L CT and 1L IO+CT patients within the study duration; causes for this warrant further inquiry.